The struggles of Novo Nordisk has economists wondering whether Denmark's economy relies too heavily on the success of the company -- and its blockbuster weight loss drugs https://t.co/oobJqrCUvI ...

Market Dynamics - Shares of Eli Lilly and Novo Nordisk experienced a decline [1] - US regulators established a "green list" of foreign manufacturers producing raw materials for GLP-1 drugs [1] Regulatory Landscape - The "green list" allows compounding pharmacies to create copies of blockbuster GLP-1 drugs [1]

Goldman Sachs and KKR are among lenders providing around €1.4 billion of one of the most expensive types of debt to back CapVest Partners’ acquisition of a majority stake in German drugmaker Stada Arzneimittel AG https://t.co/RXjEOE2v7s ...

Demand for Novo’s weight-loss blockbuster Wegovy is getting a boost in the UK from an unexpected corner: arch-rival Eli Lilly https://t.co/GLKpjCQVSC ...

All right, let's get an analyst take on this with this Eli Liy story and the future of the obesity drug market really hanging in the balance right now. David Risinger is a senior research analyst at Link Partners. He just, by the way, downgraded Eli Liy just today to a market perform from a prior outperform.He also lowered his price target from $944 down to $715. Two very significant and notable moves. David, uh, we just heard Angelica's report.It basically sets you up to take us into some more detail about ...

A widening gulf between the stock performances of Novo and its main competitor Lilly has drawn comparison with two of the world’s largest luxury-goods makers https://t.co/laJDl6f0bK ...